Contract

Senior Core Labelling Strategy Manager

Core Labelling Strategy

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

On-site in Dublin, Ireland.

Bachelor's, Master's, MBA, PhD

Category
Medical, Clinical & Veterinary (1)

Get referred to Viatris

See people who can refer or advise you

Requirements
  • Bachelor’s degree (or equivalent) in Science, Medicine, Pharmacy, or related field with typically experience, including significant labelling experience
  • Demonstrated experience in development and maintenance of global core labelling (e.g. CCDS) and major market labelling (e.g. USPI, EU SmPC)
  • Experience supporting regulatory submissions (e.g. NDA/BLA/MAA) preferred
  • Advanced degree (MSc, PharmD, PhD) is advantageous but not required
  • Experience in TPL development, competitive labelling benchmarking, and regulatory strategy support is an advantage
  • Regulatory experience with strong knowledge of global labelling across development and lifecycle management
  • Understanding of PLT and GLC governance frameworks and EU/US labelling requirements (SmPC, USPI, CCDS)
  • Experience with TPL development and competitive labelling analysis
  • Experience supporting labelling for regulatory submissions in major markets (e.g. US, EU)
  • Prior leadership experience or demonstrated ability to lead and influence others in a matrix environment
Responsibilities
  • Provide global regulatory labelling expertise and leadership to ensure Product Information (labelling) for both existing and new Viatris products is developed, maintained, and implemented in compliance with applicable regulatory requirements
  • The role is responsible for the development and maintenance of Core Labelling (including CCDS and associated patient information) and supports Global Ad Promo and Medical/Commercial material review and approval in line with company principles and procedures
  • Contributes to strategic labelling activities across the product lifecycle, including Target Product Labelling (TPL), competitive labelling analysis, and regulatory precedent assessment to support global regulatory strategy and major submissions (e.g. USPI, EU SmPC)
  • Accountable for management and delivery of labelling activities across assigned products/portfolio
  • Leads development, preparation, review, and approval of global labelling documentation (e.g. TPL, CCDS, Core Patient Information) and territorial labelling (e.g. EU SmPC, USPI) based on clinical and non-clinical data
  • Leads or supports development of labelling strategy in partnership with Global Regulatory, ensuring alignment with overall regulatory strategy and business objectives
  • Contributes to development and maintenance of Target Product Labelling (TPL) to support early development, regulatory positioning, and cross-functional alignment
  • Establishes strong cross-functional partnerships with Regulatory Strategists, Medical, Safety, and Clinical teams to ensure proactive and effective labelling development
  • Leads labelling updates and development, critically evaluating supporting data to ensure scientific accuracy, clinical relevance, and regulatory acceptability
  • Assesses and reconciles deviations from Company Core Position (e.g. CCDS) and supports responses to Health Authority requests
  • Chairs or actively contributes to Product Labelling Teams (PLTs), ensuring appropriate cross-functional input. Escalates key issues to the Global Labelling Committee (GLC) as required
  • Maintains strong awareness of competitor labelling, evolving regulatory requirements, and external trends to inform labelling strategy
  • Manages complex regulatory and scientific labelling issues, balancing compliance, business needs, and risk
  • Contributes to interpretation and application of emerging regulatory guidelines impacting labelling
  • May represent Viatris in external forums (e.g. industry groups, EMA/FDA workshops)
  • Reviews and approves promotional and non-promotional materials for alignment with CCDS and applicable codes and requirements
  • Reviews and advises on key scientific and regulatory documents (e.g. IB, protocols, CSR, PSURs, RMPs) as appropriate
  • Provides labelling expertise in cross-functional and regulatory team discussions
Desired Qualifications
  • Advanced degree (MSc, PharmD, PhD) is advantageous but not required
  • Experience in TPL development, competitive labelling benchmarking, and regulatory strategy support is an advantage

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying roughly $900 million debt.
  • Fast-acting meloxicam has a December 27, 2026 FDA action date, supporting pipeline value.

What critics are saying

  • Tyvarya rights sale to Harrow shrinks growth assets and signals portfolio pruning.
  • Merck sitagliptin litigation still threatens U.S. generic launches through 2026 appeals.
  • EpiPen settlements keep Mylan-era pricing conduct alive, risking future antitrust liabilities.

What makes Viatris unique

  • Viatris spans branded, generic, and biosimilar medicines across 165 countries.
  • Greater China delivered 21% Q2 2026 growth through established brands and e-commerce.
  • FDA-approved Gwyn Lo and meloxicam add near-term proprietary launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.

Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.